<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04792827</url>
  </required_header>
  <id_info>
    <org_study_id>IN-TF_TAVI_01</org_study_id>
    <nct_id>NCT04792827</nct_id>
  </id_info>
  <brief_title>Fast Track Concept for Transfemoral TAVI</brief_title>
  <official_title>Feasibility of a Fast Track Concept for Patients Undergoing Transfemoral Transcatheter Aortic Valve Implantation Based on Individualized Low-dose Analgosedation and Preprocedural Fluid Optimization Using Echocardiography.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Schleswig-Holstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Schleswig-Holstein</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transcatheter aortic valve implantation (TAVI) in high-risk patients with severe aortic valve&#xD;
      stenosis has developed itself until today as an established minimally invasive alternative&#xD;
      procedure worldwide, with a focus on the transfemoral access (TF-TAVI). Meanwhile a number of&#xD;
      studies have shown that analgosedation for patients undergoing TF-TAVI is a safe and feasible&#xD;
      alternative to general anaesthesia (1). The median length of stay in hospital in Europe is&#xD;
      currently 8 days independent to the anesthesia management (2). In the University Hospital&#xD;
      Schleswig-Holstein, Campus Kiel, a new TF-TAVI fast-track-concept has been implemented in&#xD;
      June 2018. The main intraprocedural aspects of the concept are the preprocedural fluid&#xD;
      optimization using transthoracic echocardiography, the idea to decrease or omit the central&#xD;
      venous line and the urinary catheter, if reasonable, and finally the individualized low-dose,&#xD;
      bolus-based AS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators are going to monitor 200 patients in 2019 treated with the newly&#xD;
      established fast-track concept. During the premedication visit, the investigators informed&#xD;
      the patients that the intention is to perform the TF-TAVI, if acceptable, solely in local&#xD;
      anaesthesia, in order to minimize potentially adverse pharmacological central effects by&#xD;
      analgosedation. After insertion of two peripheral venous lines and an arterial line,&#xD;
      monitoring of cerebral oxygenation using near-infrared spectroscopy was established.&#xD;
      Transthoracic echocardiography has been performed to evaluate volume status, using the&#xD;
      inferior vena cava collapsibility index. Additionally, cardiac output and ejection fraction&#xD;
      was calculated.&#xD;
&#xD;
      Based on the data of the investigators and current data from the literature, the&#xD;
      investigators assume a postoperative hospital stay of 8 days after TF-TAVI. With a possible&#xD;
      reduction of the hospital stay by about 25%, the investigators calculated a case number of&#xD;
      100 patients per group. The study is designed with a control group under standard therapy.&#xD;
      Data are recorded and analyzed descriptively. Qualitative comparisons will be made in the&#xD;
      discussion of previously published data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Actual">October 31, 2019</completion_date>
  <primary_completion_date type="Actual">October 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>length of stay in hospital</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>time in hospital</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>postoperative complications</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>acute renal failure, pulmonary edema, pneumonia, wound infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>one year mortality</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>survival during one year</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">200</enrollment>
  <condition>Heart Valve Diseases</condition>
  <condition>Complication,Postoperative</condition>
  <arm_group>
    <arm_group_label>analgosedation group</arm_group_label>
    <description>analgosedation concept</description>
  </arm_group>
  <arm_group>
    <arm_group_label>historical group</arm_group_label>
    <description>standard historical concept</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        TAVI-patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  scheduled for transfemoral TAVI&#xD;
&#xD;
          -  informed written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  rejection by the patient&#xD;
&#xD;
          -  switching to another procedure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein Campus Kiel - Klinik für Anästhesiologie und Operative Intensivmedizin</name>
      <address>
        <city>Kiel</city>
        <state>Deutschland (deu)</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Renner J, Tesdorpf A, Freitag-Wolf S, Francksen H, Petzina R, Lutter G, Frey N, Frank D. A retrospective study of conscious sedation versus general anaesthesia in patients scheduled for transfemoral aortic valve implantation: A single center experience. Health Sci Rep. 2018 Nov 1;2(1):e95. doi: 10.1002/hsr2.95. eCollection 2019 Jan.</citation>
    <PMID>30697594</PMID>
  </reference>
  <reference>
    <citation>Brecker SJ, Bleiziffer S, Bosmans J, Gerckens U, Tamburino C, Wenaweser P, Linke A; ADVANCE Study Investigators. Impact of Anesthesia Type on Outcomes of Transcatheter Aortic Valve Implantation (from the Multicenter ADVANCE Study). Am J Cardiol. 2016 Apr 15;117(8):1332-8. doi: 10.1016/j.amjcard.2016.01.027. Epub 2016 Jan 28.</citation>
    <PMID>26892451</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 17, 2020</study_first_submitted>
  <study_first_submitted_qc>March 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2021</study_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Schleswig-Holstein</investigator_affiliation>
    <investigator_full_name>Dr. Jochen Renner</investigator_full_name>
    <investigator_title>Prof. Dr. med. Jochen Renner</investigator_title>
  </responsible_party>
  <keyword>length of stay in hospital</keyword>
  <keyword>transfemoral transaortic valve implantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Valve Diseases</mesh_term>
    <mesh_term>Postoperative Complications</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

